{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:04:22Z","timestamp":1780628662373,"version":"3.54.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04977-3","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:49:38Z","timestamp":1776869378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ADAMDEC1 predicts prognosis and immunotherapy response in a pan-cancer study with experimental validation"],"prefix":"10.1007","volume":"17","author":[{"given":"Shuchen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"4977_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4977_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"4977_CR3","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.3747\/co.25.3750","volume":"25","author":"A Pabani","year":"2018","unstructured":"Pabani A, Butts CA. Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer. Curr Oncol. 2018;25:S94\u2013102.","journal-title":"Curr Oncol"},{"key":"4977_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1097\/RCT.0000000000001315","volume":"46","author":"M Chen","year":"2022","unstructured":"Chen M, Smith DA, Yoon JG, Vos D, Kikano EG, Tirumani SH, et al. A decade of success in melanoma immunotherapy and targeted therapy: what every radiologist should know. J Comput Assist Tomogr. 2022;46:621\u201332.","journal-title":"J Comput Assist Tomogr"},{"key":"4977_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151\u201372.","journal-title":"Nat Rev Clin Oncol"},{"key":"4977_CR6","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.3390\/ijms22094452","volume":"22","author":"YS Hah","year":"2021","unstructured":"Hah YS, Koo KC. Immunology and immunotherapeutic approaches for advanced renal cell carcinoma: a comprehensive review. Int J Mol Sci 2021; 22:4452.","journal-title":"Int J Mol Sci"},{"key":"4977_CR7","doi-asserted-by":"publisher","first-page":"102239","DOI":"10.1016\/j.ctrv.2021.102239","volume":"99","author":"F Zambrana","year":"2021","unstructured":"Zambrana F, Carril-Ajuria L, G\u00f3mez de Lia\u00f1o A, Martinez Chanza N, Manneh R, Castellano D, et al. Complete response and renal cell carcinoma in the immunotherapy era: the paradox of good news. Cancer Treat Rev. 2021;99:102239.","journal-title":"Cancer Treat Rev"},{"key":"4977_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12964-023-01315-w","volume":"21","author":"Y Yang","year":"2023","unstructured":"Yang Y, Zhu G, Yang L, Yang Y. Targeting CD24 as a novel immunotherapy for solid cancers. Cell Commun Signal. 2023;21:312.","journal-title":"Cell Commun Signal"},{"key":"4977_CR9","doi-asserted-by":"publisher","first-page":"e004711","DOI":"10.1136\/jitc-2022-004711","volume":"10","author":"EY Chiang","year":"2022","unstructured":"Chiang EY, Mellman I. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy. J Immunother Cancer 2022; 10:e004711.","journal-title":"J Immunother Cancer"},{"key":"4977_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","volume":"15","author":"B Zhao","year":"2022","unstructured":"Zhao B, Li H, Xia Y, Wang Y, Wang Y, Shi Y, et al. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy. J Hematol Oncol. 2022;15:153.","journal-title":"J Hematol Oncol"},{"key":"4977_CR11","doi-asserted-by":"publisher","first-page":"e161084","DOI":"10.1172\/JCI161084","volume":"133","author":"G Tunal\u0131","year":"2023","unstructured":"Tunal\u0131 G, R\u00fabies Bed\u00f3s M, Nagarajan D, Fridh P, Papakyriacou I, Mao Y. IL-1 receptor-associated kinase-3 acts as an immune checkpoint in myeloid cells to limit cancer immunotherapy. J Clin Invest. 2023;133:e161084.","journal-title":"J Clin Invest"},{"key":"4977_CR12","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.cell.2018.03.059","volume":"173","author":"A Blum","year":"2018","unstructured":"Blum A, Wang P, Zenklusen JC. SnapShot: TCGA-analyzed tumors. Cell. 2018;173:530.","journal-title":"Cell"},{"key":"4977_CR13","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1084\/jem.186.5.655","volume":"186","author":"CG Mueller","year":"1997","unstructured":"Mueller CG, Rissoan MC, Salinas B, Ait-Yahia S, Ravel O, Bridon JM, et al. Polymerase chain reaction selects a novel disintegrin proteinase from CD40-activated germinal center dendritic cells. J Exp Med. 1997;186:655\u201363.","journal-title":"J Exp Med"},{"key":"4977_CR14","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/j.1365-2567.2003.01754.x","volume":"110","author":"J Fritsche","year":"2003","unstructured":"Fritsche J, M\u00fcller A, Hausmann M, Rogler G, Andreesen R, Kreutz M. Inverse regulation of the ADAM-family members, decysin and MADDAM\/ADAM19 during monocyte differentiation. Immunology. 2003;110:450\u20137.","journal-title":"Immunology"},{"key":"4977_CR15","doi-asserted-by":"publisher","first-page":"21367","DOI":"10.1074\/jbc.M113.474536","volume":"288","author":"J Lund","year":"2013","unstructured":"Lund J, Olsen OH, S\u00f8rensen ES, Stennicke HR, Petersen HH, Overgaard MT. ADAMDEC1 is a metzincin metalloprotease with dampened proteolytic activity. J Biol Chem. 2013;288:21367\u201375.","journal-title":"J Biol Chem"},{"key":"4977_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s12891-022-05277-x","volume":"23","author":"L Kang","year":"2022","unstructured":"Kang L, Dai C, Wang L, Pan X. Potential biomarkers that discriminate rheumatoid arthritis and osteoarthritis based on the analysis and validation of datasets. BMC Musculoskelet Disord. 2022;23:319.","journal-title":"BMC Musculoskelet Disord"},{"key":"4977_CR17","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s10637-022-01290-y","volume":"40","author":"H Ping","year":"2022","unstructured":"Ping H, Yu W, Gong X, Tong X, Lin C, Chen Z, et al. Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine. Invest New Drugs. 2022;40:1173\u201384.","journal-title":"Invest New Drugs"},{"key":"4977_CR18","doi-asserted-by":"publisher","first-page":"1325262","DOI":"10.1155\/sci\/1325262","volume":"2025","author":"P Wang","year":"2025","unstructured":"Wang P, Xu S, Guo Q, Zhao Y. Discovery of PAK2 as a key regulator of cancer stem cell in head and neck squamous cell carcinoma using multi-omic techniques. Stem Cells Int. 2025; 2025: 1325262.","journal-title":"Stem Cells Int"},{"key":"4977_CR19","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.asjsur.2024.08.056","volume":"48","author":"S Xu","year":"2024","unstructured":"Xu S, Lu Z. The role of LMNB2 as a diagnostic and prognostic biomarker in lung adenocarcinoma. Asian J Surg. 2024;48:1175\u20137.","journal-title":"Asian J Surg"},{"key":"4977_CR20","doi-asserted-by":"crossref","unstructured":"Xu S, Lu Z. Exploring FNDC4 as a biomarker for prognosis and immunotherapy response in lung adenocarcinoma. Asian J Surg. 2024.","DOI":"10.1016\/j.asjsur.2024.09.054"},{"key":"4977_CR21","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77:e108\u201310.","journal-title":"Cancer Res"},{"key":"4977_CR22","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013102.","journal-title":"Nucleic Acids Res"},{"key":"4977_CR23","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4977_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13073-020-0721-z","volume":"12","author":"J Fu","year":"2020","unstructured":"Fu J, Li K, Zhang W, Wan C, Zhang J, Jiang P, et al. Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 2020;12:21.","journal-title":"Genome Med"},{"key":"4977_CR25","doi-asserted-by":"publisher","first-page":"10378","DOI":"10.3390\/ijms221910378","volume":"22","author":"M \u0141ukaszewicz-Zaj\u0105c","year":"2021","unstructured":"\u0141ukaszewicz-Zaj\u0105c M, Dulewicz M, Mroczko B. A Disintegrin and Metalloproteinase (ADAM) family: their significance in malignant tumors of the central nervous system (CNS). Int J Mol Sci 2021; 22:10378.","journal-title":"Int J Mol Sci"},{"key":"4977_CR26","doi-asserted-by":"publisher","first-page":"10112","DOI":"10.1074\/jbc.M116.771642","volume":"292","author":"R Chen","year":"2017","unstructured":"Chen R, Jin G, McIntyre TM. The soluble protease ADAMDEC1 released from activated platelets hydrolyzes platelet membrane pro-epidermal growth factor (EGF) to active high-molecular-weight EGF. J Biol Chem. 2017;292:10112\u201322.","journal-title":"J Biol Chem"},{"key":"4977_CR27","doi-asserted-by":"publisher","first-page":"945025","DOI":"10.3389\/fonc.2022.945025","volume":"12","author":"H Qi","year":"2022","unstructured":"Qi H, Wang P, Sun H, Li X, Hao X, Tian W, et al. ADAMDEC1 accelerates GBM progression via activation of the MMP2-related pathway. Front Oncol. 2022;12:945025.","journal-title":"Front Oncol"},{"key":"4977_CR28","doi-asserted-by":"publisher","first-page":"880945","DOI":"10.3389\/fgene.2022.880945","volume":"13","author":"L Jiang","year":"2022","unstructured":"Jiang L, Wang P, Su M, Yang L, Wang Q. Identification of mRNA signature for predicting prognosis risk of rectal adenocarcinoma. Front Genet. 2022;13:880945.","journal-title":"Front Genet"},{"key":"4977_CR29","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1158\/2159-8290.CD-18-1308","volume":"9","author":"A Jimenez-Pascual","year":"2019","unstructured":"Jimenez-Pascual A, Hale JS, Kordowski A, Pugh J, Silver DJ, Bayik D, et al. ADAMDEC1 maintains a growth factor signaling loop in cancer stem cells. Cancer Discov. 2019;9:1574\u201389.","journal-title":"Cancer Discov"},{"key":"4977_CR30","first-page":"997","volume":"35","author":"X Liu","year":"2020","unstructured":"Liu X, Huang H, Li X, Zheng X, Zhou C, Xue B, et al. Knockdown of ADAMDEC1 inhibits the progression of glioma in vitro. Histol Histopathol 2020; 35: 997\u20131005.","journal-title":"Histol Histopathol"},{"key":"4977_CR31","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/1759-7714.14354","volume":"13","author":"W Zhu","year":"2022","unstructured":"Zhu W, Shi L, Gong Y, Zhuo L, Wang S, Chen S, et al. Upregulation of ADAMDEC1 correlates with tumor progression and predicts poor prognosis in non-small cell lung cancer (NSCLC) via the PI3K\/AKT pathway. Thorac Cancer. 2022;13:1027\u201339.","journal-title":"Thorac Cancer"},{"key":"4977_CR32","doi-asserted-by":"publisher","first-page":"113629","DOI":"10.1016\/j.yexcr.2023.113629","volume":"429","author":"Y Jia","year":"2023","unstructured":"Jia Y, Huang X, Shi H, Wang M, Chen J, Zhang H, et al. ADAMDEC1 induces EMT and promotes colorectal cancer cells metastasis by enhancing Wnt\/\u03b2-catenin signaling via negative modulation of GSK-3\u03b2. Exp Cell Res. 2023;429:113629.","journal-title":"Exp Cell Res"},{"key":"4977_CR33","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1186\/s12885-021-09065-z","volume":"21","author":"S Zhang","year":"2021","unstructured":"Zhang S, Lv M, Cheng Y, Wang S, Li C, Qu X. Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature. BMC Cancer. 2021;21:1324.","journal-title":"BMC Cancer"},{"key":"4977_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/1471-2407-8-187","volume":"8","author":"DP Macartney-Coxson","year":"2008","unstructured":"Macartney-Coxson DP, Hood KA, Shi HJ, Ward T, Wiles A, O'Connor R, et al. Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level. BMC Cancer. 2008;8:187.","journal-title":"BMC Cancer"},{"key":"4977_CR35","doi-asserted-by":"publisher","first-page":"e18408","DOI":"10.1111\/jcmm.18408","volume":"28","author":"P Zhang","year":"2024","unstructured":"Zhang P, Yang Z, Liu Z, Zhang G, Zhang L, Zhang Z, et al. Deciphering lung adenocarcinoma evolution: integrative single-cell genomics identifies the prognostic lung progression associated signature. J Cell Mol Med. 2024;28:e18408.","journal-title":"J Cell Mol Med"},{"key":"4977_CR36","doi-asserted-by":"publisher","first-page":"1678907","DOI":"10.3389\/fimmu.2025.1678907","volume":"16","author":"Y Wang","year":"2025","unstructured":"Wang Y, Lu K, Xu Y, Xu S, Chu H, Fang X. Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies. Front Immunol. 2025;16:1678907.","journal-title":"Front Immunol"},{"key":"4977_CR37","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41746-025-02172-2","volume":"8","author":"Z Gong","year":"2025","unstructured":"Gong Z, Du M, Li Y, Ye B, Huang Y, Gong H, et al. Machine learning identifies TIME subtypes linking EGFR mutations and immune states in lung adenocarcinoma. NPJ Digit Med. 2025;8:796.","journal-title":"NPJ Digit Med"},{"key":"4977_CR38","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.21147\/j.issn.1000-9604.2025.06.11","volume":"37","author":"P Zhang","year":"2025","unstructured":"Zhang P, Liang X, Ye B, Wang X, Wang Y, Gong Z, et al. Metabolic reprogramming signature predicts immunotherapy efficacy in lung adenocarcinoma: Targeting SLC25A1 to overcome immune resistance. Chin J Cancer Res. 2025;37:1000\u201319.","journal-title":"Chin J Cancer Res"},{"key":"4977_CR39","doi-asserted-by":"publisher","first-page":"834731","DOI":"10.3389\/fgene.2022.834731","volume":"13","author":"S Xu","year":"2022","unstructured":"Xu S, Liu Y, Ma H, Fang S, Wei S, Li X, et al. A novel signature integrated of immunoglobulin, glycosylation and anti-viral genes to predict prognosis for breast cancer. Front Genet. 2022;13:834731.","journal-title":"Front Genet"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04977-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04977-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04977-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:17:44Z","timestamp":1780625864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04977-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4977"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04977-3","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Shanghai Zhuoli Biotechnology Company (Approval number: LLSM-15-01). All research procedures were conducted in accordance with this committee\u2019s ethical standards and the principles of the Declaration of Helsinki. The Ethics Committee waived the requirement for informed consent, as all samples used were archival paraffin-embedded cancer tissues that had been fully anonymized prior to researcher access.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"855"}}